Bora Pharmaceutical Acquires US CDMO Business for NT$3.8 Billion, Expanding Large Molecule Contract Manufacturing Footprint
Bora Pharmaceutical announced its board approved the acquisition of the CDMO (Contract Development and Manufacturing Organization) business spun off from US biopharmaceutical company MacroGenics for a total transaction value of US$122.5 million (approximately NT$3.842 billion). This includes a large molecule production facility in Rockville, Maryland, and a warehouse center in Frederick, aiming to strengthen its global biopharmaceutical contract development and manufacturing presence.
📋 Article Processing Timeline
- 📰 Published: May 12, 2026 at 11:25
- 🔍 Collected: May 12, 2026 at 11:31 (6 min after Published)
- 🤖 AI Analyzed: May 13, 2026 at 07:15 (19h 43m after Collected)
TAIPEI, May 12 (CNA) -- Bora Pharmaceutical announced today that its board of directors has approved the acquisition of the CDMO (Contract Development and Manufacturing Organization) business spun off from US biopharmaceutical company MacroGenics for a total transaction value of US$122.5 million (approximately NT$3.842 billion). The acquisition includes a large molecule production facility in Rockville, Maryland (hereinafter referred to as the Rockville plant) and a warehouse center in Frederick.
Bora Pharmaceutical stated in a press release today that after the transaction closes, the group will integrate its divisions. TaiFu Biotechnology, a key biopharmaceutical CDMO base under Bora, will collaborate with the Rockville plant. This will leverage the group's large molecule specialization, integrating TaiFu Biotechnology's San Diego plant, Bora CDMO's Maryland injectable plant, and the Rockville plant into a 'trinity' strategic role, complemented by TaiFu Taiwan's Zhubei plant, which specializes in early-stage development. This investment is expected to enhance Bora Pharmaceutical's global biopharmaceutical contract research and manufacturing layout.
Bora Pharmaceutical noted that the Rockville plant began its CDMO operations in 2022. It is equipped with five 2,000-liter and two 500-liter single-use bioreactors, as well as quality control and analytical laboratories, all of which have passed inspections by the US FDA and Japan's PMDA (Pharmaceuticals and Medical Devices Agency).
Bora Pharmaceutical stated that this transaction is expected to take over a substantial backlog of monoclonal antibody orders, including commercialized monoclonal antibody products for first-line anti-cancer drugs and breast cancer drugs, four clinical-stage projects, and potential collaborations with international pharmaceutical companies. More than half of the plant's current revenue comes from commercial production orders.
Bora Pharmaceutical Chairman Sheng Bao-hsi stated that this investment will strengthen the group's biopharmaceutical contract manufacturing platform. The global biopharmaceutical CDMO market is growing at a compound annual growth rate of 15%, while the production capacity of global biotech companies can only meet half of the market demand. With Bora Biologics (Bora Pharmaceutical's large molecule CDMO brand, authorized for use by TaiFu) global production capacity reaching 20,000 liters, the group plans to integrate its internal large molecule active pharmaceutical ingredient capabilities and fill-finish network within the next 12 to 18 months.
Bora Pharmaceutical stated that the total consideration is subject to customary working capital adjustments. Additionally, if new orders are secured through the original team in the future, Bora will pay an additional referral fee based on the order situation, with a cap of US$5 million. Bora Pharmaceutical will sign a long-term CDMO service agreement with MacroGenics upon closing.
Bora Pharmaceutical's April revenue was NT$1.484 billion, a year-on-year decrease of 27.47%; its revenue for the first four months of this year was NT$5.48 billion, a year-on-year decrease of 19.97%. (Editor: Chang Liang-chih) 1150512
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download CNA's "First-hand News" APP to stay updated with the latest news.
Text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and utilized without authorization.
Bora Pharmaceutical stated in a press release today that after the transaction closes, the group will integrate its divisions. TaiFu Biotechnology, a key biopharmaceutical CDMO base under Bora, will collaborate with the Rockville plant. This will leverage the group's large molecule specialization, integrating TaiFu Biotechnology's San Diego plant, Bora CDMO's Maryland injectable plant, and the Rockville plant into a 'trinity' strategic role, complemented by TaiFu Taiwan's Zhubei plant, which specializes in early-stage development. This investment is expected to enhance Bora Pharmaceutical's global biopharmaceutical contract research and manufacturing layout.
Bora Pharmaceutical noted that the Rockville plant began its CDMO operations in 2022. It is equipped with five 2,000-liter and two 500-liter single-use bioreactors, as well as quality control and analytical laboratories, all of which have passed inspections by the US FDA and Japan's PMDA (Pharmaceuticals and Medical Devices Agency).
Bora Pharmaceutical stated that this transaction is expected to take over a substantial backlog of monoclonal antibody orders, including commercialized monoclonal antibody products for first-line anti-cancer drugs and breast cancer drugs, four clinical-stage projects, and potential collaborations with international pharmaceutical companies. More than half of the plant's current revenue comes from commercial production orders.
Bora Pharmaceutical Chairman Sheng Bao-hsi stated that this investment will strengthen the group's biopharmaceutical contract manufacturing platform. The global biopharmaceutical CDMO market is growing at a compound annual growth rate of 15%, while the production capacity of global biotech companies can only meet half of the market demand. With Bora Biologics (Bora Pharmaceutical's large molecule CDMO brand, authorized for use by TaiFu) global production capacity reaching 20,000 liters, the group plans to integrate its internal large molecule active pharmaceutical ingredient capabilities and fill-finish network within the next 12 to 18 months.
Bora Pharmaceutical stated that the total consideration is subject to customary working capital adjustments. Additionally, if new orders are secured through the original team in the future, Bora will pay an additional referral fee based on the order situation, with a cap of US$5 million. Bora Pharmaceutical will sign a long-term CDMO service agreement with MacroGenics upon closing.
Bora Pharmaceutical's April revenue was NT$1.484 billion, a year-on-year decrease of 27.47%; its revenue for the first four months of this year was NT$5.48 billion, a year-on-year decrease of 19.97%. (Editor: Chang Liang-chih) 1150512
Choose to stand with facts, every sponsorship you make is a force to protect press freedom.
Download CNA's "First-hand News" APP to stay updated with the latest news.
Text, images, and videos on this website may not be reproduced, publicly broadcast, or publicly transmitted and utilized without authorization.